
Antonio Bellasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1355574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Retinal endothelial dysfunction: A glance on long-term risk of kidney failure. Atherosclerosis, 2022, 341, 50-51.	0.8	1
2	Bone Mineral Density Changes in Long-Term Kidney Transplant Recipients: A Real-Life Cohort Study of Native Vitamin D Supplementation. Nutrients, 2022, 14, 323.	4.1	6
3	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the) Tj ETQ	q110.78 1.6	4314 rgBT /0 14
4	The Connubium among diabetes, chronic kidney disease and atrial fibrillation. Minerva Cardiology and Angiology, 2022, , .	0.7	4
5	International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality. Npj Digital Medicine, 2022, 5, .	10.9	7
6	The "FIFTY SHADOWS―of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 3970.	2.4	1
7	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. Journal of Cardiovascular Medicine, 2022, 23, 439-446.	1.5	6
8	ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 542-544.	2.4	27
9	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	3.3	32
10	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. CKJ: Clinical Kidney Journal, 2021, 14, 366-374.	2.9	8
11	Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients. Journal of Clinical Medicine, 2021, 10, 376.	2.4	10
12	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 736-745.	4.5	11
13	Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients. Cells, 2021, 10, 1091.	4.1	5
14	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e31400.	4.3	19
15	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	5.9	33
16	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace, 2021, 23, 1603-1611.	1.7	34
17	The prognostic value of serial troponin measurements in patients admitted for COVIDâ€19. ESC Heart Failure, 2021, 8, 3504-3511.	3.1	25
18	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. International Journal of Infectious Diseases, 2021, 108, 270-273.	3.3	6

#	Article	IF	CITATIONS
19	Bone metabolism and cardiovascular disease: An overlooked association?. Atherosclerosis, 2021, 335, 87-88.	0.8	3
20	Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. Clinical Chemistry and Laboratory Medicine, 2021, 59, 581-589.	2.3	5
21	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. Journal of Clinical Medicine, 2021, 10, 83.	2.4	24
22	New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation. International Journal of Cardiology, 2021, 345, 90-97.	1.7	11
23	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	3.3	10
24	Twelve-lead electrocardiogram artefacts in patients with arteriovenous fistulas for haemodialysis. European Heart Journal - Case Reports, 2021, 5, ytab466.	0.6	0
25	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. Circulation, 2020, 141, 728-739.	1.6	104
26	New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. Journal of Nephrology, 2020, 33, 211-221.	2.0	9
27	Impact of heart failure on the clinical course and outcomes of patients hospitalized for <scp>COVID</scp> â€19. Results of the <scp>Cardio COVIDâ€Italy</scp> multicentre study. European Journal of Heart Failure, 2020, 22, 2238-2247.	7.1	99
28	Feasibility of routine ultrasound-guided percutaneous transluminal angioplasty in the treatment of native arteriovenous fistula dysfunction. Journal of Vascular Access, 2020, 22, 112972982094307.	0.9	3
29	English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. Kidney International, 2020, 98, 1352-1353.	5.2	15
30	International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. Npj Digital Medicine, 2020, 3, 109.	10.9	128
31	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	6.1	157
32	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial. Kidney International Reports, 2020, 5, 2178-2182.	0.8	11
33	ls peritoneal dialysis superior to hemodialysis as far as cardiovascular risk? Another unsolved dilemma for maintenance dialysis. Atherosclerosis, 2020, 307, 75-77.	0.8	3
34	Therapeutic management of HIV-infected patients with chronic kidney disease. Journal of Nephrology, 2020, 33, 699-713.	2.0	8
35	Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. CardioRenal Medicine, 2020, 10, 266-276.	1.9	14
36	Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. Journal of Bone and Mineral Research, 2020, 36, 500-509.	2.8	15

#	Article	IF	CITATIONS
37	Kidney Diseases: Challenges and Opportunities of the Third Millenium. How can digital health help the National Health System?. AboutOpen, 2020, 7, 1-3.	0.2	0
38	Glifozines and cardiorenal outcomes. Minerva Cardioangiologica, 2020, 68, 188-196.	1.2	0
39	Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5. Journal of Clinical Medicine, 2019, 8, 1026.	2.4	8
40	Implication of Acute Kidney Injury in Heart Failure. Heart Failure Clinics, 2019, 15, 463-476.	2.1	15
41	Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients. Journal of Clinical Medicine, 2019, 8, 1680.	2.4	2
42	Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. Journal of Nephrology, 2019, 32, 989-1001.	2.0	104
43	Chronic Kidney Disease: The Silent Epidemy. Journal of Clinical Medicine, 2019, 8, 1795.	2.4	14
44	Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus, 2019, 3, e10242.	2.7	28
45	Coronary artery calcium in the general population, patients with chronic kidney disease and diabetes mellitus. , 2019, , 159-180.		0
46	Kidney Disease in HIV Infection. Journal of Clinical Medicine, 2019, 8, 1254.	2.4	35
47	Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study). Journal of Clinical Medicine, 2019, 8, 1424.	2.4	81
48	Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights. Journal of Clinical Medicine, 2019, 8, 718.	2.4	10
49	Ultrafiltrazione peritoneale e sindrome cardiorenale: gestione del sovraccarico di fluidi e ruolo del sodio. Giornale De Techniche Nefrologiche & Dialitiche, 2019, 31, 100-105.	0.1	Ο
50	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	1.9	17
51	Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future. Giornale De Techniche Nefrologiche & Dialitiche, 2019, 31, 30-36.	0.1	0
52	Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. Journal of Nephrology, 2019, 32, 635-643.	2.0	16
53	Associations between echocardiographic findings and prospective changes in residual renal function in patients new to peritoneal dialysis. Scientific Reports, 2019, 9, 18434.	3.3	1
54	Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?. International Journal of Cardiology, 2019, 274, 179-185.	1.7	13

#	Article	IF	CITATIONS
55	Cardiorenal Syndrome in Acute Kidney Injury. Seminars in Nephrology, 2019, 39, 31-40.	1.6	45
56	Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options. CardioRenal Medicine, 2019, 9, 8-21.	1.9	19
57	Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. International Journal of Cardiology, 2019, 278, 243-249.	1.7	41
58	CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy. Journal of Nephrology, 2018, 31, 585-591.	2.0	4
59	Vascular inflammation: A call for a specific and sensitive biomarker?. Atherosclerosis, 2018, 271, 235-236.	0.8	4
60	Cardiovascular calcification: The emerging role of micronutrients. Atherosclerosis, 2018, 273, 119-121.	0.8	11
61	Nutritional therapy in autosomal dominant polycystic kidney disease. Journal of Nephrology, 2018, 31, 635-643.	2.0	14
62	Among markers of risk, uric acid remains a two-faced Janus awaiting definitive framing. Atherosclerosis, 2018, 272, 219-221.	0.8	4
63	Assessment of intradialysis calcium mass balance by a single pool variableâ€volume calcium kinetic model. Hemodialysis International, 2018, 22, 126-135.	0.9	11
64	Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 804-813.	0.7	45
65	Search for a reliable biomarker of acute kidney injury: to the heart of the problem. Annals of Translational Medicine, 2018, 6, S5-S5.	1.7	3
66	Cardiorenal Syndrome: An Overview. Advances in Chronic Kidney Disease, 2018, 25, 382-390.	1.4	109
67	Chronic kidney disease: A model of impaired vascular remodeling. Atherosclerosis, 2018, 279, 88-90.	0.8	2
68	Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. Journal of Nephrology, 2018, 31, 751-756.	2.0	32
69	The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S295-S305.	3.6	16
70	Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease. Expert Review of Clinical Pharmacology, 2017, 10, 1073-1084.	3.1	14
71	Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. International Journal of Cardiology, 2017, 227, 143-150.	1.7	37
72	Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Therapeutics and Clinical Risk Management, 2017, Volume 13, 679-689.	2.0	27

#	Article	IF	CITATIONS
73	Type-5 Cardiorenal Syndrome (CRS-5): An up to Date. Nephrology @ Point of Care, 2017, 3, napoc.5000212.	0.2	1
74	Phosphate Management in Patients With End-Stage Renal Disease. , 2017, , 698-705.e2.		0
75	Epidemiology of low-proteinuric chronic kidney disease in renal clinics. PLoS ONE, 2017, 12, e0172241.	2.5	26
76	Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease. Current Drug Metabolism, 2017, 18, 680-688.	1.2	4
77	Con: Phosphate binders in chronic kidney diseaseOpponent's comments. Nephrology Dialysis Transplantation, 2016, 31, gfv406.	0.7	6
78	Pro: Should phosphate binders be used in chronic kidney disease stage 3–4?Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, gfv405.	0.7	11
79	Single-Center Open-Label Randomized Study of Anemia Management Improvement in ESRD Patients with Secondary Hyperparathyroidism. Nephrology @ Point of Care, 2016, 2, pocj.5000196.	0.2	0
80	Coronary artery disease (CAD) in chronic kidney disease patients. Giornale De Techniche Nefrologiche & Dialitiche, 2016, 28, 44-52.	0.1	1
81	Retarding CKD Progression: Readily Available through Comprehensive Nutritional Management?. Nephrology @ Point of Care, 2016, 2, pocj.5000202.	0.2	1
82	Serum calcium may not accurately predict intradialytic calcium mass transfer. Hemodialysis International, 2016, 20, 331-332.	0.9	1
83	Shed a light on intradialytic calcium mass balance. Kidney International, 2016, 89, 1402.	5.2	1
84	Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology, 2016, 29, 683-690.	2.0	11
85	The density of calcified plaques and the volume of calcium predict mortality in hemodialysis patients. Atherosclerosis, 2016, 250, 166-171.	0.8	29
86	Prediction of hard cardiovascular events in HIV patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3515-3518.	3.0	20
87	Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrology, 2016, 17, 158.	1.8	66
88	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 194-195.	0.7	1
89	Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology, 2016, 86, 113-124.	0.7	9
90	Nephrology@Point of Care: A New Journal for Hands-On Clinicians. Nephrology @ Point of Care, 2015, 1, napoc.2015.1468.	0.2	0

#	Article	IF	CITATIONS
91	Ivabradine, Heart Failure and Chronic Kidney Disease. Nephrology @ Point of Care, 2015, 1, poc.5000190.	0.2	3
92	Cardiovascular Biomarkers in Chronic Kidney Disease: State of Current Research and Clinical Applicability. Disease Markers, 2015, 2015, 1-16.	1.3	36
93	SP575PREDICTIVE VALUE OF MEASURES OF VASCULAR CALCIFICATION FOR RISK OF DEATH IN INCIDENT DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii568-iii568.	0.7	0
94	Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. CKJ: Clinical Kidney Journal, 2015, 8, 732-736.	2.9	46
95	Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients. Journal of Cardiovascular Computed Tomography, 2015, 9, 553-558.	1.3	31
96	The Importance of Ventricular-Vascular Uncoupling. JACC: Heart Failure, 2015, 3, 95.	4.1	1
97	Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology, 2015, 28, 593-602.	2.0	11
98	Emerging drugs for secondary hyperparathyroidism. Expert Opinion on Emerging Drugs, 2015, 20, 197-208.	2.4	24
99	Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology, 2015, 28, 73-80.	2.0	33
100	Vascular calcification, bone and mineral metabolism after kidney transplantation. World Journal of Transplantation, 2015, 5, 222.	1.6	14
101	Vitamina D nativa o attivata: quale forma Ã indispensabile?. Giornale De Techniche Nefrologiche & Dialitiche, 2015, 27, 143-144.	0.1	0
102	Not all diabetic patients were created equal: How to discriminate risk?. Atherosclerosis, 2014, 237, 82-83.	0.8	3
103	Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?. Nephro-Urology Monthly, 2014, 6, e18379.	0.1	1
104	Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study. Blood Purification, 2014, 37, 316-324.	1.8	11
105	Physical Activity in Chronic Kidney Disease: a Plausible Approach to Vascular Calcification?. Kidney and Blood Pressure Research, 2014, 39, 154-163.	2.0	2
106	Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. Atherosclerosis, 2014, 237, 618-622.	0.8	6
107	Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias. Journal of Antimicrobial Chemotherapy, 2014, 69, 284-285.	3.0	1
108	Integration of clinical and imaging data to predict death in hemodialysis patients. Hemodialysis International, 2013, 17, 12-18.	0.9	10

#	Article	IF	CITATIONS
109	Hybrid myocardial imaging for risk stratification prior to kidney transplantation: Added value of coronary calcium and epicardial adipose tissue. Journal of Nuclear Cardiology, 2013, 20, 1013-1020.	2.1	21
110	Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial. American Journal of Kidney Diseases, 2013, 62, 771-778.	1.9	156
111	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. Calcified Tissue International, 2013, 93, 413-418.	3.1	8
112	Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrology Dialysis Transplantation, 2013, 28, 632-640.	0.7	73
113	Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation, 2013, 28, 2586-2595.	0.7	39
114	Vitamin D Status and Coronary Flow Reserve Measured by Positron Emission Tomography: A Co-Twin Control Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 389-397.	3.6	16
115	Which Vitamin D in CKD-MBD? The Time of Burning Questions. BioMed Research International, 2013, 2013, 1-10.	1.9	22
116	Does It Make Sense to Measure Only the Brachial Blood Pressure?. Blood Purification, 2013, 36, 21-25.	1.8	14
117	Cinacalcet: the chemical parathyroidectomy?. CKJ: Clinical Kidney Journal, 2013, 6, 253-256.	2.9	5
118	Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice. Blood Purification, 2013, 36, 12-16.	1.8	1
119	QT interval in CKD and haemodialysis patients. CKJ: Clinical Kidney Journal, 2013, 6, 137-143.	2.9	15
120	Phosphate binders in moderate chronic kidney disease: where do we stand?. Journal of Nephrology, 2013, 26, 993-1000.	2.0	11
121	Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease?. Journal of Nephrology, 2013, 26, 606-609.	2.0	3
122	Phosphate Balance and Organ Damage. Giornale De Techniche Nefrologiche & Dialitiche, 2013, 25, 208-212.	0.1	0
123	[Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes]. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia. 2013. 30.	0.3	3
124	Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. Journal of Heart Valve Disease, 2013, 22, 391-9.	0.5	20
125	What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2013, 30, .	0.3	5
126	Mortality in Kidney Disease Patients Treated with Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 487-493.	4.5	209

#	Article	IF	CITATIONS
127	Vascular imaging in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2012, 21, 382-388.	2.0	33
128	Impact of Vascular Calcification on QT Interval and QT Dispersion in CKD and Dialysis Patients. American Journal of Nephrology, 2012, 35, 287-287.	3.1	3
129	Blood pressure variability and outcomes in chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 4404-4410.	0.7	64
130	Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease. Current Hypertension Reviews, 2012, 8, 244-249.	0.9	0
131	Is time on cardiopulmonary bypass during cardiac surgery associated with acute kidney injury requiring dialysis?. Hemodialysis International, 2012, 16, 252-258.	0.9	9
132	Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients. Journal of Nephrology, 2012, 25, 211-218.	2.0	34
133	Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease. Current Hypertension Reviews, 2012, 8, 244-249.	0.9	0
134	Variability of pulse wave velocity and mortality in chronic hemodialysis patients. Hemodialysis International, 2011, 15, 326-333.	0.9	13
135	Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 883-891.	4.5	128
136	All-cause Mortality in Hemodialysis Patients with Heart Valve Calcification. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1990-1995.	4.5	96
137	Arterial Stiffness in Chronic Kidney Disease: The Usefulness of a Marker of Vascular Damage. International Journal of Nephrology, 2011, 2011, 1-5.	1.3	22
138	Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients. Kidney and Blood Pressure Research, 2011, 34, 180-187.	2.0	42
139	Vascular calcification in chronic kidney disease: usefulness of a marker of vascular damage. Journal of Nephrology, 2011, 24, 11-15.	2.0	20
140	Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of) Tj ETQq0 0 (Or g₿6 T/Ov	erl o ck 10 Tf 5
141	Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification. Current Vascular Pharmacology, 2009, 7, 374-380.	1.7	14
142	How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?. Journal of Nephrology, 2009, 22, 255-62.	2.0	31
143	Impact of race and chronic kidney disease on 1-year outcome in patients undergoing percutaneous coronary interventions: A single tertiary center experience. American Heart Journal, 2008, 155, 1027-1032.	2.7	9
144	Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis, 2008, 199, 424-431.	0.8	114

#	ARTICLE	IF	CITATIONS
145	Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality. American Journal of Epidemiology, 2008, 169, 67-77.	3.4	86
146	Cardiovascular Calcium: Assessment and Impact of Interventions. , 2008, , 1-6.		0
147	New insights into ischemic heart disease in women. Journal of the California Dental Association, 2008, 36, 107-14.	0.1	3
148	Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients. Hypertension, 2007, 49, 1278-1284.	2.7	73
149	Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 26-33.	3.3	49
150	Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus. British Journal of Diabetes and Vascular Disease, 2007, 7, 157-164.	0.6	0
151	Clinical Assessment of Vascular Calcification. Advances in Chronic Kidney Disease, 2007, 14, 37-43.	1.4	29
152	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Techniques and Technologies to Assess Vascular Calcification. Seminars in Dialysis, 2007, 20, 129-133.	1.3	38
153	Comparison of Prognostic Usefulness of Coronary Artery Calcium in Men Versus Women (Results) Tj ETQq1 1 0.7	784314 rş 1.6	gBT /Overloc 92
154	New insights into ischemic heart disease in women Cleveland Clinic Journal of Medicine, 2007, 74, 585-594.	1.3	36
155	Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. Future Lipidology, 2006, 1, 375-379.	0.5	1
156	Phosphate binders: New products and challenges. Hemodialysis International, 2006, 10, 225-234.	0.9	44
157	Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation, 2006, 21, 3215-3222.	0.7	65
158	Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients. Nephrology Dialysis Transplantation, 2006, 22, 508-514.	0.7	25
159	Diagnostic and prognostic value of coronary artery calcium screening. Current Opinion in Cardiology, 2005, 20, 375-380.	1.8	23
160	Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 165-171.	1.7	4
161	Ischemia Imaging and Plaque Imaging in Diabetes: Complementary tools to improve cardiovascular risk management. Diabetes Care, 2005, 28, 2787-2794.	8.6	29